ABIVAX SA (ABVX.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ABVX - FR0012333284 - Common Stock
ABVX.PA Key Statistics, Chart & Performance
The current stock price of ABVX.PA is 94.4 EUR. In the past month the price increased by 6.51%. In the past year, price increased by 1069.17%.
ABVX.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 74.35 | 48.75B | ||
| ARGX.BR | ARGENX SE | 72.39 | 47.47B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.91B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.22B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.78B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.80B | ||
| 5CV.DE | CUREVAC NV | 5.06 | 991.20M | ||
| NANO.PA | NANOBIOTIX | N/A | 887.16M | ||
| PHIL.MI | PHILOGEN SPA | 20.61 | 687.14M | ||
| IVA.PA | INVENTIVA SA | N/A | 662.45M | ||
| 6IV.DE | INVENTIVA SA | N/A | 672.38M | ||
| FYB.DE | FORMYCON AG | N/A | 440.87M |
Related stock screener links
About ABVX.PA
Company Profile
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 67 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Company Info
ABIVAX SA
7-11 Boulevard Haussmann
Paris ILE-DE-FRANCE FR
Employees: 69
Phone: 33153830963
ABIVAX SA / ABVX.PA FAQ
What does ABVX do?
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 67 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
What is the current price of ABVX stock?
The current stock price of ABVX.PA is 94.4 EUR. The price increased by 1.18% in the last trading session.
Does ABIVAX SA pay dividends?
ABVX.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ABVX stock?
ABVX.PA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does ABIVAX SA belong to?
ABIVAX SA (ABVX.PA) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for ABVX stock?
ABIVAX SA (ABVX.PA) currently has 69 employees.
What is ABIVAX SA worth?
ABIVAX SA (ABVX.PA) has a market capitalization of 7.35B EUR. This makes ABVX.PA a Mid Cap stock.
ABVX.PA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ABVX.PA. When comparing the yearly performance of all stocks, ABVX.PA is one of the better performing stocks in the market, outperforming 99.64% of all stocks.
ABVX.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ABVX.PA. Both the profitability and financial health of ABVX.PA have multiple concerns.
ABVX.PA Financial Highlights
Over the last trailing twelve months ABVX.PA reported a non-GAAP Earnings per Share(EPS) of -2.8. The EPS increased by 18.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -105.39% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ABVX.PA Forecast & Estimates
14 analysts have analysed ABVX.PA and the average price target is 105.35 EUR. This implies a price increase of 11.6% is expected in the next year compared to the current price of 94.4.
For the next year, analysts expect an EPS growth of -3.38% and a revenue growth 91.53% for ABVX.PA